Accueil
mcv4
Illustration of time at risk of IMD, MCV4 vaccination uptake and

Illustration of time at risk of IMD, MCV4 vaccination uptake and

4.5 (567) · € 35.00 · En Stock

Download scientific diagram | Illustration of time at risk of IMD, MCV4 vaccination uptake and duration of protection from MCV4 in all cohorts studied. IMD = Invasive meningococcal disease, MCV4 = meningococcal ACWY conjugate vaccine from publication: Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine | In Norway, the incidence of invasive meningococcal disease (IMD) is higher among 16–19-year-olds than in the general population. Most IMD cases among teenagers are caused by serogroup Y. Since 2011, one dose of meningococcal ACWY conjugate vaccine (MCV4) has been recommended | Meningococcal Vaccines, Conjugate Vaccines and Vaccines | ResearchGate, the professional network for scientists.

Download PDF - OMICS Group

Epidemiology of vaccine-preventable diseases in Japan: considerations for pre-travel advice for the 2019 Rugby World Cup and 2020 Summer Olympic and Paralympic Games

Epidemiology of invasive meningococcal disease in Greece, 2006–2016

Longitudinal study of meningococcal carriage rates in university entrants living in a dormitory in South Korea

Immunization Recommendations: - ppt download

Preventing Invasive meningococcal disease in < 2 year children in India

Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs, BMC Public Health